{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:17:50Z","timestamp":1779297470919,"version":"3.51.4"},"reference-count":73,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Studying primary melanoma and its corresponding metastasis has twofold benefits. Firstly, to better understand tumor biology, and secondly, to determine which sample should be examined in assessing drug targets. This study systematically analyzed all the literature on primary melanoma and its matched metastasis. Following PRISMA guidelines, we searched multiple medical databases for relevant publications from January 2000 to December 2022, assessed the quality of the primary-level studies using the QUIPS tool, and summarized the concordance rate of the most reported genes using the random-effects model. Finally, we evaluated the inter-study heterogeneity using the subgroup analysis. Thirty-one studies investigated the concordance of BRAF and NRAS in 1220 and 629 patients, respectively. The pooled concordance rate was 89.4% [95% CI: 84.5; 93.5] for BRAF and 97.8% [95% CI: 95.8; 99.4] for NRAS. When high-quality studies were considered, only BRAF mutation status consistency increased. Five studies reported the concordance status of c-KIT (93%, 44 patients) and TERT promoter (64%, 53 patients). Lastly, three studies analyzed the concordance of cancer genes involved in the signaling pathways, apoptosis, and proliferation, such as CDKN2A (25%, four patients), TP53 (44%, nine patients), and PIK3CA (20%, five patients). Our study found that the concordance of known drug targets (mainly BRAF) during melanoma progression is higher than in previous meta-analyses, likely due to advances in molecular techniques. Furthermore, significant heterogeneity exists in the genes involved in the melanoma genetic makeup; although our results are based on small patient samples, more research is necessary for validation.<\/jats:p>","DOI":"10.3390\/ijms242216281","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T02:20:37Z","timestamp":1699928437000},"page":"16281","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-1792","authenticated-orcid":false,"given":"Thamila","family":"Kerkour","sequence":"first","affiliation":[{"name":"Department of Dermatology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7157-6341","authenticated-orcid":false,"given":"Catherine","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loes","family":"Hollestein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-5780","authenticated-orcid":false,"given":"Antien","family":"Mooyaart","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","article-title":"The growing burden of invasive melanoma: Projections of incidence rates and numbers of new cases in six susceptible populations through 2031","volume":"136","author":"Whiteman","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 Validated in two independent cohorts: Implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"adv00502","DOI":"10.2340\/00015555-3832","article-title":"Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence","volume":"101","author":"Ertekin","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhou, C., Louwman, M., Wakkee, M., Van der Veldt, A., Gr\u00fcnhagen, D., Verhoef, C., Mooyaart, A., Nijsten, T., and Hollestein, L. (2021). Primary melanoma characteristics of metastatic disease: A nationwide cancer registry study. Cancers, 13.","DOI":"10.3390\/cancers13174431"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdq438","article-title":"Phase 3 study of docosahexaenoic acid\u2013paclitaxel versus dacarbazine in patients with metastatic malignant melanoma","volume":"22","author":"Bedikian","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2013Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/path.2804","article-title":"A new era: Melanoma genetics and therapeutics","volume":"223","author":"Ko","year":"2011","journal-title":"J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41388-022-02244-7","article-title":"Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147\/VEGFR-2 interaction","volume":"41","author":"Landras","year":"2022","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11912-012-0249-5","article-title":"Driver mutations in melanoma: Lessons learned from bench-to-bedside studies","volume":"14","author":"Mehnert","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and melanoma: Biological insights and clinical implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.05.015","article-title":"Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis","volume":"81","author":"Valachis","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_21","first-page":"218","article-title":"Richtlijn Melanoom: Modulaire revisie 2016","volume":"13","year":"2016","journal-title":"Ned. Tijdschr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"gkad347","DOI":"10.1093\/nar\/gkad347","article-title":"g: Profiler\u2014Interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update)","volume":"51","author":"Kolberg","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00266-022-02977-6","article-title":"Using Freeman-Tukey Double Arcsine Transformation in Meta-analysis of Single Proportions","volume":"47","author":"Chen","year":"2023","journal-title":"Aesthetic Plast. Surg."},{"key":"ref_25","first-page":"40","article-title":"meta: An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_27","first-page":"6483","article-title":"NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R.L., Berman, R.S., Pavlick, A.C., Darvishian, F., Christos, P., and Mazumdar, M. (2012). Intra- and inter-tumor heterogeneity of BRAFV600Emutations in primary and metastatic melanoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029336"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1479-5876-11-202","article-title":"Heterogeneous distribution of BRAF\/NRAS mutations among Italian patients with advanced melanoma","volume":"11","author":"Colombino","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jdermsci.2013.07.013","article-title":"KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma","volume":"72","author":"Zebary","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.yexmp.2014.09.008","article-title":"Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy","volume":"97","author":"Saroufim","year":"2014","journal-title":"Exp. Mol. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/modpathol.2014.136","article-title":"Discordancy in BRAF mutations among primary and metastatic melanoma lesions: Clinical implications for targeted therapy","volume":"28","author":"Bradish","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamadermatol.2014.3689","article-title":"BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases","volume":"151","author":"Eriksson","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CMR.0000000000000166","article-title":"BRAF mutation screening in melanoma: Is sentinel lymph node reliable?","volume":"25","author":"Nardin","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1038\/jid.2015.229","article-title":"Intra- and inter-tumoral homogeneity of BRAF V600E mutations in melanoma tumors","volume":"135","author":"Villanueva","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","article-title":"Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients","volume":"80","author":"Sakaizawa","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37895","DOI":"10.18632\/oncotarget.5634","article-title":"Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma","volume":"6","author":"Satzger","year":"2015","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/DAD.0000000000000404","article-title":"BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study with Pyrosequencing and Immunohistochemistry","volume":"38","author":"Yaman","year":"2016","journal-title":"Am. J. Dermatopathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.18632\/oncotarget.14094","article-title":"Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry","volume":"8","author":"Bruno","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e8404","DOI":"10.1097\/MD.0000000000008404","article-title":"The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases","volume":"96","author":"Hannan","year":"2017","journal-title":"Medicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdermsci.2016.10.006","article-title":"Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity","volume":"85","author":"Kaji","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/his.13431","article-title":"Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases","volume":"72","author":"Nielsen","year":"2018","journal-title":"Histopathology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.humpath.2018.08.002","article-title":"Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples","volume":"82","author":"Yang","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/cup.13393","article-title":"High concordance of BRAF mutational status in matched primary and metastatic melanoma","volume":"46","author":"Cormican","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ito, T., Kaku-Ito, Y., Murata, M., Ichiki, T., Kuma, Y., Tanaka, Y., Ide, T., Ohno, F., Wada-Ohno, M., and Yamada, Y. (2019). Intra-and inter-tumor braf heterogeneity in acral melanoma: An immunohistochemical analysis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246191"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12967-019-2039-4","article-title":"Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach","volume":"17","author":"Manca","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Mejbel, H.A., Arudra, S.K.C., Pradhan, D., Torres-Cabala, C.A., Nagarajan, P., Tetzlaff, M.T., Curry, J.L., Ivan, D., Duose, D.Y., and Luthra, R. (2019). Immunohistochemical and molecular features of melanomas exhibiting intratumor and intertumor histomorphologic heterogeneity. Cancers, 11.","DOI":"10.3390\/cancers11111714"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jid.2020.01.027","article-title":"TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors","volume":"140","author":"Chang","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"adv00040","DOI":"10.2340\/00015555-3382","article-title":"Intra-patient heterogeneity of BRAF and NRAS molecular alterations in primary melanoma and metastases","volume":"100","author":"Pellegrini","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.0022-202x.2001.01601.x","article-title":"Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma","volume":"117","author":"Demunter","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","first-page":"3468","article-title":"Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: Mutations occur early and persist throughout tumor progression","volume":"8","author":"Omholt","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"Akslen","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10147-013-0573-2","article-title":"NRAS mutations in primary and metastatic melanomas of Japanese patients","volume":"19","author":"Uhara","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: What do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcmr.12459","article-title":"The genomic landscape of cutaneous melanoma","volume":"29","author":"Zhang","year":"2016","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41467-021-21576-8","article-title":"Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling","volume":"12","author":"Vergara","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Cherepakhin, O.S., Argenyi, Z.B., and Moshiri, A.S. (2021). Genomic and transcriptomic underpinnings of melanoma genesis, progression, and metastasis. Cancers, 14.","DOI":"10.3390\/cancers14010123"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10555-016-9613-5","article-title":"Genetic progression of malignant melanoma","volume":"35","author":"Vizkeleti","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clon.2014.09.014","article-title":"Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer","volume":"27","author":"Wang","year":"2015","journal-title":"Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.cca.2011.01.014","article-title":"BRAFV600E detection in melanoma is highly improved by COLD-PCR","volume":"412","author":"Pinzani","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"18592","DOI":"10.1038\/srep18592","article-title":"Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients","volume":"5","author":"Barbano","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p. V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing","volume":"15","author":"Colomba","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12935-023-02858-1","article-title":"BRAFV600E mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population","volume":"23","author":"Yakout","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.humpath.2014.08.018","article-title":"Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma","volume":"46","author":"Thiel","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ardito, F., Razionale, F., Salvatore, L., Cenci, T., Vellone, M., Basso, M., Panettieri, E., Calegari, M.A., Tortora, G., and Martini, M. (2021). Discordance of KRAS mutational status between primary tumors and liver metastases in colorectal cancer: Impact on long-term survival following radical resection. Cancers, 13.","DOI":"10.3390\/cancers13092148"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ebiom.2019.01.050","article-title":"Biomarker concordance between primary colorectal cancer and its metastases","volume":"40","author":"Bhullar","year":"2019","journal-title":"eBioMedicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bcp.2017.12.019","article-title":"The biology and therapeutic management of melanoma brain metastases","volume":"153","author":"Ramello","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000074156","article-title":"Drug resistance in human melanoma: Mechanisms and therapeutic opportunities","volume":"26","author":"Schadendorf","year":"2003","journal-title":"Oncol. Res. Treat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1038\/srep08065","article-title":"Concordant analysis of KRAS, BRAF, PIK3CA mutations and PTEN expression between primary colorectal cancer and matched metastases","volume":"5","author":"Mao","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jnci\/djp309","article-title":"Polyclonality of BRAF mutations in acquired melanocytic nevi","volume":"101","author":"Lin","year":"2009","journal-title":"JNCI J. Natl. Cancer Inst."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16281\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:22:37Z","timestamp":1760131357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":73,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242216281"],"URL":"https:\/\/doi.org\/10.3390\/ijms242216281","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}